^
Association details:
| Biomarker: | BRCA1 2080delA |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + fadraciclib (CYC065) (CDK9 inhibitor, CDK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition
Published date:
08/31/2021
Excerpt:
We tested in vivo efficacy of the combination therapy in two PDXs of BLBC origin with pathogenic BRCA1 alterations: BRCA1 R1443* mutation and truncating BRCA1 2080delA mutation...each model was treated with daily gavage of 50 mg/kg olaparib (a PARP inhibitor) and 25 mg/kg fadraciclib...The combination of CDK2 inhibition with PARP inhibition leads to tumor regression and improved survival in BRCA1 mutant PDX models.
DOI:
https://doi.org/10.1038/s41523-021-00312-x
